DK2451514T3 - Dosage unit, dosage unit pack and inhaler for inhalation of a combination of drugs - Google Patents
Dosage unit, dosage unit pack and inhaler for inhalation of a combination of drugs Download PDFInfo
- Publication number
- DK2451514T3 DK2451514T3 DK10730861.1T DK10730861T DK2451514T3 DK 2451514 T3 DK2451514 T3 DK 2451514T3 DK 10730861 T DK10730861 T DK 10730861T DK 2451514 T3 DK2451514 T3 DK 2451514T3
- Authority
- DK
- Denmark
- Prior art keywords
- pockets
- dose
- powder
- pharmaceutically active
- dosage unit
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims description 89
- 229940079593 drug Drugs 0.000 title claims description 79
- 239000000843 powder Substances 0.000 claims description 105
- 239000004480 active ingredient Substances 0.000 claims description 46
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 claims description 18
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 claims description 18
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 18
- 229960002052 salbutamol Drugs 0.000 claims description 18
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 17
- 239000000556 agonist Substances 0.000 claims description 16
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims description 13
- 229940112141 dry powder inhaler Drugs 0.000 claims description 12
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 11
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 11
- 229960004436 budesonide Drugs 0.000 claims description 11
- 229940124750 glucocorticoid receptor agonist Drugs 0.000 claims description 11
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims description 9
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims description 9
- YREYLAVBNPACJM-UHFFFAOYSA-N 2-(tert-butylamino)-1-(2-chlorophenyl)ethanol Chemical compound CC(C)(C)NCC(O)C1=CC=CC=C1Cl YREYLAVBNPACJM-UHFFFAOYSA-N 0.000 claims description 9
- IHOXNOQMRZISPV-YJYMSZOUSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-methoxyphenyl)propan-2-yl]azaniumyl]ethyl]-2-oxo-1h-quinolin-8-olate Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 IHOXNOQMRZISPV-YJYMSZOUSA-N 0.000 claims description 9
- 229960003060 bambuterol Drugs 0.000 claims description 9
- ANZXOIAKUNOVQU-UHFFFAOYSA-N bambuterol Chemical compound CN(C)C(=O)OC1=CC(OC(=O)N(C)C)=CC(C(O)CNC(C)(C)C)=C1 ANZXOIAKUNOVQU-UHFFFAOYSA-N 0.000 claims description 9
- 229950010713 carmoterol Drugs 0.000 claims description 9
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims description 9
- 229960002179 ephedrine Drugs 0.000 claims description 9
- 229960001022 fenoterol Drugs 0.000 claims description 9
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims description 9
- 229960002848 formoterol Drugs 0.000 claims description 9
- 229960001317 isoprenaline Drugs 0.000 claims description 9
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 claims description 9
- 229960002657 orciprenaline Drugs 0.000 claims description 9
- -1 perenzepine Chemical compound 0.000 claims description 9
- 229960005205 prednisolone Drugs 0.000 claims description 9
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 9
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 9
- 229960004618 prednisone Drugs 0.000 claims description 9
- 229960002720 reproterol Drugs 0.000 claims description 9
- WVLAAKXASPCBGT-UHFFFAOYSA-N reproterol Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCCNCC(O)C1=CC(O)=CC(O)=C1 WVLAAKXASPCBGT-UHFFFAOYSA-N 0.000 claims description 9
- 229960001457 rimiterol Drugs 0.000 claims description 9
- IYMMESGOJVNCKV-SKDRFNHKSA-N rimiterol Chemical compound C([C@@H]1[C@@H](O)C=2C=C(O)C(O)=CC=2)CCCN1 IYMMESGOJVNCKV-SKDRFNHKSA-N 0.000 claims description 9
- 239000012453 solvate Substances 0.000 claims description 9
- 229960000195 terbutaline Drugs 0.000 claims description 9
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 claims description 9
- 229940110309 tiotropium Drugs 0.000 claims description 9
- 229960002117 triamcinolone acetonide Drugs 0.000 claims description 9
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims description 9
- 229960000859 tulobuterol Drugs 0.000 claims description 9
- VSWPGAIWKHPTKX-UHFFFAOYSA-N 1-methyl-10-[2-(4-methyl-1-piperazinyl)-1-oxoethyl]-5H-thieno[3,4-b][1,5]benzodiazepin-4-one Chemical compound C1CN(C)CCN1CC(=O)N1C2=CC=CC=C2NC(=O)C2=CSC(C)=C21 VSWPGAIWKHPTKX-UHFFFAOYSA-N 0.000 claims description 8
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 claims description 8
- 229960001888 ipratropium Drugs 0.000 claims description 8
- NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 claims description 8
- 229960000797 oxitropium Drugs 0.000 claims description 8
- 229960001802 phenylephrine Drugs 0.000 claims description 8
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims description 8
- 229960004017 salmeterol Drugs 0.000 claims description 8
- 229950004351 telenzepine Drugs 0.000 claims description 8
- OYYDSUSKLWTMMQ-JKHIJQBDSA-N trospium Chemical compound [N+]12([C@@H]3CC[C@H]2C[C@H](C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 OYYDSUSKLWTMMQ-JKHIJQBDSA-N 0.000 claims description 8
- 229960001491 trospium Drugs 0.000 claims description 8
- 102000007202 Muscarinic M3 Receptor Human genes 0.000 claims description 7
- 108010008405 Muscarinic M3 Receptor Proteins 0.000 claims description 7
- 229940092705 beclomethasone Drugs 0.000 claims description 7
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims description 7
- 239000000812 cholinergic antagonist Substances 0.000 claims description 7
- 230000009977 dual effect Effects 0.000 claims description 7
- 229940044601 receptor agonist Drugs 0.000 claims description 7
- 239000000018 receptor agonist Substances 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 238000009826 distribution Methods 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 239000003149 muscarinic antagonist Substances 0.000 claims description 6
- ASMXXROZKSBQIH-VITNCHFBSA-N aclidinium Chemical compound C([C@@H](C(CC1)CC2)OC(=O)C(O)(C=3SC=CC=3)C=3SC=CC=3)[N+]21CCCOC1=CC=CC=C1 ASMXXROZKSBQIH-VITNCHFBSA-N 0.000 claims description 3
- 229940019903 aclidinium Drugs 0.000 claims description 3
- 229960000289 fluticasone propionate Drugs 0.000 claims description 3
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims description 3
- 229960005018 salmeterol xinafoate Drugs 0.000 claims description 3
- OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 claims description 2
- JFUAWXPBHXKZGA-IBGZPJMESA-N 4-fluoro-2-[(4r)-5,5,5-trifluoro-4-hydroxy-2-methyl-4-(1h-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-yl]phenol Chemical compound C([C@@](O)(CC=1NC2=CN=CC=C2C=1)C(F)(F)F)C(C)(C)C1=CC(F)=CC=C1O JFUAWXPBHXKZGA-IBGZPJMESA-N 0.000 claims description 2
- 239000000048 adrenergic agonist Substances 0.000 claims description 2
- 229940124748 beta 2 agonist Drugs 0.000 claims description 2
- 229960000193 formoterol fumarate Drugs 0.000 claims description 2
- 102000014974 beta2-adrenergic receptor activity proteins Human genes 0.000 claims 2
- 108040006828 beta2-adrenergic receptor activity proteins Proteins 0.000 claims 2
- LSLYOANBFKQKPT-UHFFFAOYSA-N fenoterol Chemical compound C=1C(O)=CC(O)=CC=1C(O)CNC(C)CC1=CC=C(O)C=C1 LSLYOANBFKQKPT-UHFFFAOYSA-N 0.000 claims 2
- 108060003345 Adrenergic Receptor Proteins 0.000 claims 1
- 102000017910 Adrenergic receptor Human genes 0.000 claims 1
- DYUQAZSOFZSPHD-UHFFFAOYSA-N Phenylpropanol Chemical compound CCC(O)C1=CC=CC=C1 DYUQAZSOFZSPHD-UHFFFAOYSA-N 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 229950009195 phenylpropanol Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 7
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 7
- HUYWAWARQUIQLE-UHFFFAOYSA-N Isoetharine Chemical compound CC(C)NC(CC)C(O)C1=CC=C(O)C(O)=C1 HUYWAWARQUIQLE-UHFFFAOYSA-N 0.000 description 7
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 7
- 229960003728 ciclesonide Drugs 0.000 description 7
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 7
- 229960000676 flunisolide Drugs 0.000 description 7
- 229960002714 fluticasone Drugs 0.000 description 7
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 229960001268 isoetarine Drugs 0.000 description 7
- 229960001664 mometasone Drugs 0.000 description 7
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 229960000395 phenylpropanolamine Drugs 0.000 description 7
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 7
- 229960005414 pirbuterol Drugs 0.000 description 7
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 229960001375 lactose Drugs 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000011888 foil Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 2
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 2
- 229950000210 beclometasone dipropionate Drugs 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000010902 jet-milling Methods 0.000 description 2
- 229960001021 lactose monohydrate Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 239000000472 muscarinic agonist Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 238000004804 winding Methods 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010053582 Bronchopneumopathy Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 101100503636 Danio rerio fyna gene Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 101150018272 FYN gene Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 239000003458 I kappa b kinase inhibitor Substances 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 102000015617 Janus Kinases Human genes 0.000 description 1
- 108010024121 Janus Kinases Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 101710141394 MAP kinase-activated protein kinase 2 Proteins 0.000 description 1
- 102100034069 MAP kinase-activated protein kinase 2 Human genes 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229940122694 Muscarinic M3 receptor antagonist Drugs 0.000 description 1
- 208000000592 Nasal Polyps Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 102000048176 Prostaglandin-D synthases Human genes 0.000 description 1
- 108030003866 Prostaglandin-D synthases Proteins 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 102000000551 Syk Kinase Human genes 0.000 description 1
- 108010016672 Syk Kinase Proteins 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 239000002465 adenosine A2a receptor agonist Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000035874 hyperreactivity Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960004873 levomenthol Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000003681 muscarinic M3 receptor antagonist Substances 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 1
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- PJFHZKIDENOSJB-JIVDDGRNSA-N symbicort inhalation aerosol Chemical compound C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O PJFHZKIDENOSJB-JIVDDGRNSA-N 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000001238 wet grinding Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0003—Details of inhalators; Constructional features thereof with means for dispensing more than one drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
- A61M15/0031—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up by bursting or breaking the package, i.e. without cutting or piercing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
- A61M15/0046—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier
- A61M15/0048—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier the dosages being arranged in a plane, e.g. on diskettes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
- A61M15/0046—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier
- A61M15/0051—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier the dosages being arranged on a tape, e.g. strips
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0061—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using pre-packed dosages having an insert inside
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D83/00—Containers or packages with special means for dispensing contents
- B65D83/06—Containers or packages with special means for dispensing contents for dispensing powdered or granular material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Mechanical Engineering (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Packages (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22344109P | 2009-07-07 | 2009-07-07 | |
| PCT/IB2010/052888 WO2011004287A1 (en) | 2009-07-07 | 2010-06-24 | Dose unit, pack of dose units and inhaler for inhalation of combination of drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2451514T3 true DK2451514T3 (en) | 2017-07-03 |
Family
ID=42732534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10730861.1T DK2451514T3 (en) | 2009-07-07 | 2010-06-24 | Dosage unit, dosage unit pack and inhaler for inhalation of a combination of drugs |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9561336B2 (https=) |
| EP (1) | EP2451514B1 (https=) |
| JP (1) | JP5801997B2 (https=) |
| KR (1) | KR101419141B1 (https=) |
| CN (1) | CN102481424B (https=) |
| AR (1) | AR077459A1 (https=) |
| AU (1) | AU2010269899B2 (https=) |
| CA (1) | CA2767306C (https=) |
| CY (1) | CY1119441T1 (https=) |
| DK (1) | DK2451514T3 (https=) |
| ES (1) | ES2629833T3 (https=) |
| HU (1) | HUE034595T2 (https=) |
| IL (1) | IL217404A (https=) |
| MX (1) | MX348345B (https=) |
| PL (1) | PL2451514T3 (https=) |
| PT (1) | PT2451514T (https=) |
| SG (1) | SG177444A1 (https=) |
| SI (1) | SI2451514T1 (https=) |
| TW (1) | TWI561260B (https=) |
| WO (1) | WO2011004287A1 (https=) |
| ZA (1) | ZA201200221B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1844808A1 (de) * | 2006-04-13 | 2007-10-17 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | Medikamenten-Ausgabevorrichtung |
| JP6140143B2 (ja) | 2011-03-21 | 2017-05-31 | シムプリフィード ソリューションズ スウェーデン エービー | 粉末形態の物質用の吸入器 |
| AU2013202919C1 (en) * | 2012-07-03 | 2016-02-04 | Advent Pharmaceuticals Pty Ltd | Blister Pack |
| SE537715C2 (sv) * | 2013-11-26 | 2015-10-06 | Simplified Solutions Sweden Ab | Inhalationsanordning för ämnen i pulverform |
| CN105013054B (zh) * | 2015-07-30 | 2018-11-09 | 中山市美捷时包装制品有限公司 | 一种多胶囊型干粉吸入装置 |
| CN104984448B (zh) * | 2015-07-30 | 2018-05-01 | 中山市美捷时包装制品有限公司 | 一种干粉吸入器 |
| KR101992171B1 (ko) * | 2017-06-27 | 2019-06-25 | 한국유나이티드제약 주식회사 | 건조분말 흡입기 |
| US20200324064A1 (en) * | 2019-04-10 | 2020-10-15 | Cai Gu Huang | Inhalation Device for Administering Powdered Pharmaceutical Composition |
| US12225935B2 (en) | 2019-10-04 | 2025-02-18 | Philip Morris Products S.A. | Aerosol-generating devices |
| GB2589635B (en) * | 2019-12-06 | 2021-12-01 | Merxin Ltd | Elongate form medicament carrier and medicament dispenser |
| DE112019007971A5 (de) * | 2019-12-18 | 2022-09-22 | Markus Mezger | Inhalator |
| US20240139440A1 (en) * | 2021-01-28 | 2024-05-02 | Iconovo Ab | Medicament packaging |
| EP4284474B1 (en) * | 2021-01-28 | 2026-04-29 | Iconovo AB | Dry powder inhaler |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9920839D0 (en) * | 1999-09-04 | 1999-11-10 | Innovata Biomed Ltd | Inhaler |
| US6971383B2 (en) * | 2001-01-24 | 2005-12-06 | University Of North Carolina At Chapel Hill | Dry powder inhaler devices, multi-dose dry powder drug packages, control systems, and associated methods |
| US7931022B2 (en) * | 2001-10-19 | 2011-04-26 | Respirks, Inc. | Method and apparatus for dispensing inhalator medicament |
| DE60230546D1 (de) | 2001-10-26 | 2009-02-05 | Pharmacia & Upjohn Co Llc | Quaternäre ammoniumverbindungen und deren verwendung als antimuscarinische wirkstoffe |
| GB0201677D0 (en) | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | Medicament dispenser |
| US7153903B1 (en) | 2002-06-19 | 2006-12-26 | The Board Of Regents Of The University Of Oklahoma | Carbon nanotube-filled composites prepared by in-situ polymerization |
| GB0217196D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicament dispenser |
| EP1556034B1 (en) | 2002-10-11 | 2008-04-16 | Pfizer Limited | Indole derivatives as beta-2 agonists |
| GB0315509D0 (en) | 2003-07-02 | 2003-08-06 | Meridica Ltd | Dispensing device |
| PT1708992E (pt) | 2004-01-22 | 2007-11-16 | Pfizer | Derivados de sulfonamida para o tratamento de doenças |
| EP1708991B1 (en) | 2004-01-22 | 2007-10-17 | Pfizer Limited | Sulfonamide derivatives for the treatment of diseases |
| EA200601510A1 (ru) | 2004-03-17 | 2007-04-27 | Пфайзер Инк. | Производные фенилэтаноламина в качестве бета-2-агонистов |
| EP1730103B1 (en) | 2004-03-23 | 2010-05-26 | Pfizer Limited | Formamide derivatives useful as adrenoceptor |
| SE0402976L (sv) * | 2004-12-03 | 2006-06-04 | Mederio Ag | Medicinsk produkt |
| NZ585580A (en) | 2005-07-18 | 2011-08-26 | Pfizer Ltd | Process for the preparation of sulfonamide derivatives |
| WO2007034325A1 (en) | 2005-09-21 | 2007-03-29 | Pfizer Limited | Carboxamide derivatives as muscarinic receptor antagonists |
| RS20080411A (sr) | 2006-03-20 | 2009-07-15 | Pfizer Limited, | Derivati amina |
| US20100160279A1 (en) | 2006-09-22 | 2010-06-24 | Pfizer Inc | Azetidine Derivatives as Muscarinic Receptor Antagonists |
| AP2009004791A0 (en) | 2006-10-04 | 2009-04-30 | Pfizer Ltd | Sulfonamide derivatives as adrenergic agonists andmuscarinic antagonists |
| WO2008056370A2 (en) * | 2006-11-19 | 2008-05-15 | Aespira Ltd. | Dry-powder inhaler |
| EP1992380A1 (en) * | 2007-05-16 | 2008-11-19 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dispensing device |
| PE20090136A1 (es) * | 2007-06-01 | 2009-03-11 | Boehringer Ingelheim Int | Dispositivo dispensador |
| CA2699463A1 (en) | 2007-09-14 | 2009-03-19 | Pfizer Limited | Novel compounds active as muscarinic receptor antagonists |
-
2010
- 2010-06-10 JP JP2010132837A patent/JP5801997B2/ja not_active Expired - Fee Related
- 2010-06-24 HU HUE10730861A patent/HUE034595T2/en unknown
- 2010-06-24 CN CN201080037227.3A patent/CN102481424B/zh active Active
- 2010-06-24 DK DK10730861.1T patent/DK2451514T3/en active
- 2010-06-24 PL PL10730861T patent/PL2451514T3/pl unknown
- 2010-06-24 SG SG2011097474A patent/SG177444A1/en unknown
- 2010-06-24 MX MX2012000430A patent/MX348345B/es active IP Right Grant
- 2010-06-24 SI SI201031475A patent/SI2451514T1/sl unknown
- 2010-06-24 CA CA2767306A patent/CA2767306C/en active Active
- 2010-06-24 AU AU2010269899A patent/AU2010269899B2/en active Active
- 2010-06-24 KR KR1020127003170A patent/KR101419141B1/ko not_active Expired - Fee Related
- 2010-06-24 ES ES10730861.1T patent/ES2629833T3/es active Active
- 2010-06-24 PT PT107308611T patent/PT2451514T/pt unknown
- 2010-06-24 EP EP10730861.1A patent/EP2451514B1/en active Active
- 2010-06-24 WO PCT/IB2010/052888 patent/WO2011004287A1/en not_active Ceased
- 2010-06-24 US US13/380,083 patent/US9561336B2/en active Active
- 2010-07-06 TW TW099122153A patent/TWI561260B/zh not_active IP Right Cessation
- 2010-07-07 AR ARP100102448A patent/AR077459A1/es active IP Right Grant
-
2012
- 2012-01-05 IL IL217404A patent/IL217404A/en active IP Right Grant
- 2012-01-11 ZA ZA2012/00221A patent/ZA201200221B/en unknown
-
2017
- 2017-06-12 CY CY20171100618T patent/CY1119441T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2451514A1 (en) | 2012-05-16 |
| AU2010269899B2 (en) | 2013-06-13 |
| JP2011015958A (ja) | 2011-01-27 |
| JP5801997B2 (ja) | 2015-10-28 |
| US9561336B2 (en) | 2017-02-07 |
| IL217404A0 (en) | 2012-02-29 |
| MX2012000430A (es) | 2012-02-13 |
| CA2767306C (en) | 2014-05-20 |
| KR101419141B1 (ko) | 2014-07-11 |
| MX348345B (es) | 2017-06-06 |
| CY1119441T1 (el) | 2018-03-07 |
| EP2451514B1 (en) | 2017-04-26 |
| ZA201200221B (en) | 2013-03-27 |
| SI2451514T1 (sl) | 2017-07-31 |
| HUE034595T2 (en) | 2018-02-28 |
| CN102481424A (zh) | 2012-05-30 |
| AU2010269899A1 (en) | 2012-02-02 |
| US20120111327A1 (en) | 2012-05-10 |
| CA2767306A1 (en) | 2011-01-13 |
| WO2011004287A1 (en) | 2011-01-13 |
| PT2451514T (pt) | 2017-06-21 |
| SG177444A1 (en) | 2012-02-28 |
| CN102481424B (zh) | 2014-05-07 |
| KR20120042932A (ko) | 2012-05-03 |
| AR077459A1 (es) | 2011-08-31 |
| TW201106997A (en) | 2011-03-01 |
| TWI561260B (en) | 2016-12-11 |
| ES2629833T3 (es) | 2017-08-16 |
| IL217404A (en) | 2014-12-31 |
| PL2451514T3 (pl) | 2017-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2451514T3 (en) | Dosage unit, dosage unit pack and inhaler for inhalation of a combination of drugs | |
| US9795751B2 (en) | Dry powder inhaler | |
| US20070017513A1 (en) | Method and apparatus for dispensing inhalator medicament | |
| EP2566546B1 (en) | Dry powder inhaler mouthpiece button | |
| TWI494142B (zh) | 吸入器（四） | |
| JP2011015958A5 (https=) | ||
| EP2558148B1 (en) | Dry powder inhaler mouthpiece button | |
| WO2011129790A1 (en) | Inhaler which creates turbulance | |
| EP2558149A1 (en) | Dry powder inhaler mouthpiece button | |
| EP3194033A1 (en) | Spacer device with flow rate spirometer | |
| JP5873477B2 (ja) | 乾燥粉末形態の薬剤の送達に使用する吸入器 | |
| HK1169050B (en) | Dose unit, pack of dose units and inhaler for inhalation of combination of drugs | |
| HK1169050A (en) | Dose unit, pack of dose units and inhaler for inhalation of combination of drugs | |
| WO2014161901A1 (en) | Metering element for an inhalation device and assembly for an inhalation device comprising a metering element | |
| AU2002362991A1 (en) | Method and apparatus for dispensing inhalator medicament |